Out with electric vehicles, in with weight loss drugs: Investors have ditched one-time favorite Tesla for pharmaceutical giant Eli Lilly, as the early days of long-established Eli Lilly's diabetes and
Eli Lilly (LLY) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.09 per share a year ago.
Eli Lilly shares jumped in premarket Tuesday after the company reported better-than-expected fourth quarter results and revised its 2024 forecast ahead of expectations, amid soaring demand for its dia
7:00am: Modest falls expected; Eli Lilly jumps on earnings beat Stock futures in New York edged lower on Tuesday as investors braced for another busy day of corporate news. In pre-market trading, futu
Shares of Eli Lilly and Co. LLY, +5.77% rallied toward a fifth-straight record close in premarket trading Tuesday, after the drug maker's fourth-quarter earnings beat expectations, helped by a 16% jum
Louise Chen, Cantor Fitzgerald, joins 'Fast Money' to talk Eli Lilly ahead of earnings.
When finding stocks to own, growth stocks are a top priority. For those looking to invest with a truly long-term investing time horizon, growth stocks tend to outperform.
Artificial intelligence grabbed most of the headlines last year, but weight loss stocks were equally noteworthy. It grew slowly for several years but really went stratospheric last year.
Nowadays, the market sends mixed signals to virtually every investor attempting to participate today, squeezing out a few percentage points of gains from the stock movements. With the Federal Reserv
The U.S. Food and Drug Administration's website said some doses of Eli Lilly's diabetes drug Mounjaro are available only in limited quantities through early March 2024.
Eli Lilly is a leader in one of the fastest-growing pharmaceutical segments today: the weight-loss market. The company recently released a new treatment specifically approved for weight management.
The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retainin
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quart

Why Eli Lilly Stock Topped the Market Today

06:16pm, Wednesday, 31'st Jan 2024
A rival posted highly encouraging annual results for 2023. A great deal of its growth was due to a certain category of medications Eli Lilly also has in its product lineup.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE